Compare Abbott Laboratories (ABT) vs Avalanche Treasury Corporation Class A Common Stock (AVAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Avalanche Treasury Corporation Class A Common Stock — how do they compare? Abbott Laboratories trades at $95.39 (market cap $166.94B), while Avalanche Treasury Corporation Class A Common Stock trades at $0.5 (market cap $20.14M). The key difference: Abbott Laboratories is far larger — about 8289× Avalanche Treasury Corporation Class A Common Stock's market cap, and Abbott Laboratories pays a 2.63% dividend while Avalanche Treasury Corporation Class A Common Stock pays none. Which is the better fit depends on your goals.
| ABT | AVAT | |
|---|---|---|
Market Cap | $166.94B | $20.14M |
Sector | Health | Financials |
52-Week High | $136.62 | $10.75 |
52-Week Low | $82.57 | $0.51 |
Enterprise Value | $193.69B | $20.14M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
AVAT trades at $0.5114, down 3.22% today, with a bearish technical signal from moving averages and a neutral oscillator reading. The company reported a net income of $8.28 million for 2025 but shows negative operating cash flow of -$930,710. Recent news highlights its Nasdaq listing as Avalanche Treasury Co., focusing on capital allocation within its ecosystem.
The outlook is cautious due to weak cash flow and bearish technicals, though low P/E and P/B ratios may appeal to value investors. Key risks include operational sustainability and market sentiment shifts. Analyst consensus is not yet established post-listing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →
